고위험 증식당뇨망막병증에서 범망막광응고술과 유리체강내 베바시주맙 병합치료의 장기간 효과

• 영문명: Long-term Effect of Panretinal Photocoagulation Combined With Intravitreal Bevacizumab in High-risk Proliferative Diabetic Retinopathy
• 발행기관: 대한안과학회
• 저자명: 최준호 이성진 최경식,Jun Ho Choi, MD, Sung Jin Lee, MD, PhD, Kyung Seek Choi, MD, PhD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume51,number6, 842~848쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2010.06.15

영문 초록

Purpose: To evaluate long-term effects and usefulness of combined intravitreal injection of bevacizumab and panretinal photocoagulation (PRP) in patients with high-risk proliferative diabetic retinopathy. Methods: The authors retrospectively reviewed the records of 40 patients (40 eyes) with high-risk proliferative diabetic retinopathy who had been treated with PRP alone (laser treatment group, n=20) or intravitreal bevacizumab before PRP (combined treatment group, n=20). Changes in best corrected visual acuity (BCVA), central macular thickness (CMT) and the total area of leakage from active new vessels (NVs) were compared between the groups at one, three, and six months and at one year post-treatment. Results: In the combined treatment group, CMT decreased significantly at one month (p=0.021), and the areas of active NVs decreased significantly at one month (p=0.001) and three months (p=0.014) compared to those of the laser treatment group. However, there were no differences between the two groups after three months. In the combined treatment group, elevated intraocular pressures were found in three cases after one month, and there were vitreous hemorrhages in two cases after three months. Conclusions: The combined treatment showed significant early improvements in BCVA, CMT, and NVs regression for up to three months. However, long-term follow-up and additional treatment was necessary in the patients with persistent or recurred NVs and macular edema after three months. J Korean Ophthalmol Soc 2010;51(6):842-848

키워드

Bevacizumab, High risk proliferative diabetic retinopathy (PDR), Proliferative diabetic retinopathy (PDR), Panretinal photocoagulation (PRP)